Perisurgical physiopathology and pain

The Perisurgical physiopathology and pain group carries out research in the areas of traumatology, emergency medicine and emergency medical care.

374 Publications

Strategic lines

Selected Publications

Garcia Casanovas,A;Bisbe,E;Garcia Altes,A;Vizoso,A;Duran Jorda,X;Sanchez Pedrosa,G;Barquero,M et al, Hospital variation in quality indicators for patient blood management in total knee and hip arthroplasty: a retrospective cohort study, Br. J. Anaesth., 2024;133(3):637-646, doi:10.1016/j.bja.2024.05.019
Andrés Benito,P;Vázquez Costa,JF;Garzón,NCN;Colomina,MJ;Marco,C;González,L;Terrafeta,C et al, Neurodegeneration Biomarkers in Adult Spinal Muscular Atrophy (SMA) Patients Treated with Nusinersen, Int J Mol Sci, 2024;25(7):doi:10.3390/ijms25073810
Blasi,A;Garcia Criado,A;Moreno Rojas,J;Perez Serrano,C;Ubre,M;Dieguez,I;Panzeri,M et al, A multicenter study of the risk of major bleeding in patients with and without cirrhosis undergoing percutaneous liver procedures., Liver Transpl, 2024;doi:10.1097/LVT.0000000000000447
Roca Pereira,S;Domínguez,R;León,IM;Colomina,MJ;Yélamos,AM;Yélamos,SM;Povedano,M et al, Increased CXCL12, a potential CSF biomarker for differential diagnosis of amyotrophic lateral sclerosis, Brain Commun, 2024;6(4):doi:10.1093/braincomms/fcae271
Borrego Hernández,D;Vázquez Costa,JF;Domínguez Rubio,R;Expósito Blázquez,L;Aller,E;Padró Miquel,A;García Casanova,P et al, Intermediate Repeat Expansion in the ATXN2Gene as a Risk Factor in the ALS and FTD Spanish Population, Biomedicines, 2024;12(2):doi:10.3390/biomedicines12020356

Selected Projects

2019-003502-28. Estudio en grupos paralelos, doble ciego, aleatorizado y controlado por placebo, para evaluar la eficacia y seguridad de AP-325 en pacientes con Dolor Neuropático Periférico Post-quirúrgico. Algiax Pharmaceuticals GmbH. Budget: 34.860€. 2020- . PI: Andrés Ancor Serrano Afonso.
2022-131-1. Ensayo clínico de intervención en fase iii, multicéntrico, aleatorizado, con doble enmascaramiento, controlado y con grupos paralelos para confirmar la eficacia y la seguridad de Qutenza®en pacientes con Dolor Neuropático Posquirúrgico. AVERITAS PHARMA, INC. Budget: 30.312€. 2022- . PI: Andrés Ancor Serrano Afonso.
2023-507358-34-00. Multicenter, doublé-blind, randomized, placebo-controlled, dose response trial with the full-spectrum Cannabis Extract VER-01 in patients with chronic non-specific low back pain.. Vertanical GmbH. Budget: 12.584,01€. 2024- . PI: Andrés Ancor Serrano Afonso.
PSJ23039. Artificial intelligence (AI) to facilitate surgery. Use Case Proofof-Concept in Breast Cancer Surgery for a New Innovative Artificial Intelligence Automated Pre- Anesthesia Risk Assessment Tool. Jané Mateu Foundation. Budget: 6.000€. 2023-2024. PI: Colomina Soler, Maria Jose.
2023-223-1. POSTOPERATIVE PULMONARY COMPLICATIONS IN EMERGENCY ABDOMINAL SURGERY. INCIDENCE AND RISK FACTORS. A PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY. Hospital Clínic de Barcelona. 2023- . PI: Marta Costa Reverte.